Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 3/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3732650 | 0.98 | CXCR3 (0.96) | CXCR3KCNH2ALDH1A1DPP4LMNA | |
| SCHEMBL3732867 | 0.94 | CXCR3 (0.88) | CXCR3KCNH2ALDH1A1DPP4LMNA | |
| SCHEMBL3735739 | 0.94 | CXCR3 (0.88) | CXCR3KCNH2ALDH1A1DPP4LMNA | |
| SCHEMBL3730735 | 0.94 | CXCR3 (0.88) | CXCR3KCNH2ALDH1A1DPP4LMNA | |
| SCHEMBL3735454 | 0.93 | CXCR3 (0.86) | CXCR3KCNH2ALDH1A1DPP4LMNA | |
| SCHEMBL3740353 | 0.92 | CXCR3 (0.85) | CXCR3KCNH2ALDH1A1DPP4LMNA | |
| SCHEMBL3730784 | 0.92 | CXCR3 (0.85) | CXCR3KCNH2ALDH1A1DPP4LMNA | |
| SCHEMBL3726591 | 0.92 | CXCR3 (0.84) | CXCR3KCNH2ALDH1A1LMNAKMT2A | |
| SCHEMBL3740276 | 0.92 | CXCR3 (0.84) | CXCR3KCNH2ALDH1A1DPP4LMNA | |
| SCHEMBL3742966 | 0.92 | CXCR3 (0.84) | CXCR3KCNH2ALDH1A1DPP4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11359011-B2 | Treatment and prevention of cardiovascular disease | Edifice Health, Inc. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20210315921-A1 | Compounds and Methods for Modifying iAge | Edifice Health, Inc. (US) | 2021-10-14 | — | — | US | disclosed |
| US-20210040195-A1 | Treatment and Prevention of Cardiovascular Disease | Edifice Health, Inc. (US) | 2021-02-11 | — | — | US | disclosed |
| US-8450317-B2 | CXCR3 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-28 | — | — | US | disclosed |
| EP-2424840-A1 | CXCR3 RECEPTOR ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010126811-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | WO | disclosed |
| US-20100280028-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280028-A1 | CXCR3 RECEPTOR ANTAGONISTS | CXCR3, CXCR1, CXCR2 | CXCR3 1/4885KCNH2 1561/4885ALDH1A1 1298/4885 |
| US-20210315921-A1 | Compounds and Methods for Modifying iAge | LIPG, IFNG, CD40LG | CXCR3 244/4885KCNH2 2867/4885ALDH1A1 700/4885 |
| US-20210040195-A1 | Treatment and Prevention of Cardiovascular Disease | SERPINA6, FABP3, CXCL8 | CXCR3 835/4885KCNH2 3076/4885ALDH1A1 2390/4885 |
| US-11359011-B2 | Treatment and prevention of cardiovascular disease | SERPINA6, FABP3, CXCL8 | CXCR3 835/4885KCNH2 3076/4885ALDH1A1 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.